Kura Oncology (KURA) investor relations material

Executive summary

• KOMZIFTI achieved majority share of new patient starts in relapsed/refractory NPM1-mutated AML menin inhibitor market in its second full commercial quarter, generating $9.1 million in net product revenue for Q2 2026 and $14.9 million for the first half of 2026, with over 250 total prescriptions and 115 new patient starts.

• Physician adoption is expanding, with 40% of new patient starts involving combination therapy, and coverage now exceeds 95% of insured lives, including 16 million with preferred status.

• Clinical data for ziftomenib and darlifarnib support their potential as foundational therapies in AML and solid tumors, with robust response rates and manageable safety profiles.

• The company is executing on a strategy to build two differentiated precision oncology franchises, supported by strong commercial execution and disciplined capital allocation.

• KOMZIFTI was approved by the FDA in November 2025 and added to NCCN Guidelines as a recommended treatment.

Financial highlights

• Net product revenue from KOMZIFTI sales was $9.1 million in Q2 2026 and $14.9 million for the first half of 2026.

• Collaboration revenue from Kyowa Kirin was $11.8 million in Q2 2026 and $24.3 million for the first half of 2026.

• Research and development expenses were $61.9 million in Q2 2026 and $127.2 million for the first half of 2026.

• Selling, general, and administrative expenses increased to $31.8 million in Q2 2026 and $63.3 million for the first half of 2026.

• Net loss was $68.3 million in Q2 2026 and $141.7 million for the first half of 2026.

• Cash, equivalents, and short-term investments totaled $519 million as of June 30, 2026.

Outlook and guidance

• Collaboration revenue guidance maintained at $45–$55 million for 2026, $90–$110 million for 2027 and 2028.

• Cash and anticipated collaboration payments are expected to fund the ziftomenib AML program through top-line phase III results in 2028.

• Multiple clinical updates and key data readouts expected in the second half of 2026 and 2027, including monotherapy, combination therapy, and new treatment settings.

• Enrollment for the pivotal KOMET-017 trial is progressing well, with top-line results expected in 2028.